Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 20/20 | 1.00 |
| ▸ | ATR | Q13535 | 4/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.77 |
| ▸ | MTOR | P42345 | 11/20 | 0.73 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18631949 | 1.00 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL18632019 | 0.99 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL18631935 | 0.98 | ATM (0.97) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL19584960 | 0.92 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL18824736 | 0.89 | ATM (0.81) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL19605306 | 0.88 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL19585082 | 0.88 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL19585078 | 0.88 | ATM (1.00) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL18632002 | 0.88 | ATM (0.79) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL18824613 | 0.88 | ATM (0.78) | ATMATRKCNH2MTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-11613539-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-03-28 | — | — | US | disclosed |
| EP-3683220-B1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1-ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF HUNTINGTON'S DISEASE | ASTRAZENECA AB (SE) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11613539-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ATM, BRCA1, CHEK2 | ATM 1/4885ATR 10/4885KCNH2 2560/4885 |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | ATM 1/4885ATR 10/4885KCNH2 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.